Literature DB >> 16860263

Thiazide diuretics for hypertension: prescribing practices and predictors of use in 194,761 elderly patients with hypertension.

Karen Tu1, Norman R C Campbell, Zhongliang Chen, Finlay A McAlister.   

Abstract

BACKGROUND: Although several small studies have reported underuse of thiazide diuretics for elderly hypertensive patients, those factors which influence initial choice of first-line antihypertensive treatment are unknown.
OBJECTIVES: : The objective of this study was to explore prescribing practices for antihypertensives in the elderly and determine which factors are associated with thiazide diuretic use as first-line treatment
METHODS: This population-based cohort study used linked administrative databases for all elderly patients (> or =66 years of age) first treated for hypertension between July 1, 1994, and March 31, 2002, in Ontario, Canada.
RESULTS: Of the 194,761 patients in our cohort, 68,858 (35%) were prescribed a thiazide diuretic as their first anti-hypertensive agent. On multivariate analysis, factors associated with being prescribed a thiazide as first-line treatment included age (adjusted odds ratio [AOR], 1.72 [95% CI, 1.67-1.78] for octogenarians compared with patients aged 66-69 years) and having multiple comorbidities (AOR, 1.24 [95% CI, 1.16-1.29] for Charlson scores of 2 and AOR, 1.52 [95% CI, 1.37-1.61] for Charlson scores of > or =3). On the other hand, men (AOR, 0.64 [95% CI 0.63-0.65]) and hypertensives with diabetes (AOR, 0.22 [95% CI, 0.21-0.23]) were substantially less likely to be prescribed thiazide diuretics as first-line treatment. Socioeconomic status was not associated with use of thiazide diuretics.
CONCLUSIONS: One third of initial antihypertensive prescriptions for elderly patients were for thiazides in our publicly funded health care system with universal drug coverage. Socioeconomic status did not influence use of thiazides, but age, sex, and comorbidities did.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860263     DOI: 10.1016/j.amjopharm.2006.06.004

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  7 in total

Review 1.  Olmesartan in the treatment of hypertension in elderly patients: a review of the primary evidence.

Authors:  Massimo Volpe; Giuliano Tocci
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

2.  Antihypertensive medication prescribing patterns in a university teaching hospital.

Authors:  R Neal Axon; Paul J Nietert; Brent M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-04       Impact factor: 3.738

3.  Management of hypertension in elderly long-term care residents.

Authors:  Ross T Tsuyuki; Donna L McLean; Finlay A McAlister
Journal:  Can J Cardiol       Date:  2008-12       Impact factor: 5.223

4.  Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.

Authors:  Joaquin A Alvarez Gregori; Juan F Macías Nuñez; Alfonso Domínguez-Gil
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Diuretics for hypertension-reasons for a contradiction in primary care prescribing behavior: a qualitative study.

Authors:  Henrik Lamers; Stefanie Joos; Katja Goetz; Katja Hermann; Joachim Szecsenyi; Thomas Kühlein
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-07-09       Impact factor: 3.738

6.  Prevalence, prescribing and barriers to effective management of hypertension in older populations: a narrative review.

Authors:  Tariq M Alhawassi; Ines Krass; Lisa G Pont
Journal:  J Pharm Policy Pract       Date:  2015-10-14

7.  Printed educational messages fail to increase use of thiazides as first-line medication for hypertension in primary care: a cluster randomized controlled trial [ISRCTN72772651].

Authors:  Merrick Zwarenstein; Jeremy M Grimshaw; Justin Presseau; Jill J Francis; Gaston Godin; Marie Johnston; Martin P Eccles; Jacqueline Tetroe; Susan K Shiller; Ruth Croxford; Diane Kelsall; J Michael Paterson; Peter C Austin; Karen Tu; Lingsong Yun; Janet E Hux
Journal:  Implement Sci       Date:  2016-09-17       Impact factor: 7.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.